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Strong Association of De Novo Copy
Number Mutations with Autism
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We tested the hypothesis that de novo copy number variation (CNV) is associated with autism
spectrum disorders (ASDs). We performed comparative genomic hybridization (CGH) on the
genomic DNA of patients and unaffected subjects to detect copy number variants not present in
their respective parents. Candidate genomic regions were validated by higher-resolution CGH,
paternity testing, cytogenetics, fluorescence in situ hybridization, and microsatellite genotyping.
Confirmed de novo CNVs were significantly associated with autism (P = 0.0005). Such CNVs were
identified in 12 out of 118 (10%) of patients with sporadic autism, in 2 out of 77 (3%) of patients
with an affected first-degree relative, and in 2 out of 196 (1%) of controls. Most de novo CNVs
were smaller than microscopic resolution. Affected genomic regions were highly heterogeneous
and included mutations of single genes. These findings establish de novo germline mutation as a
more significant risk factor for ASD than previously recognized.
Autism spectrum disorders (ASDs) [Men-delian Inheritance inMan (MIM) 209850]are characterized by language impair-
ments, social deficits, and repetitive behaviors.
The onset of symptoms occurs by the age of 3 and
usually requires extensive support for the lifetime
of the afflicted. The prevalence of ASD is es-
timated to be 1 in 166 (1), making it a major
burden to society.
Genetics plays a major role in the etiology of
autism. The concordance rates in monozygotic
twins are 70% for autism and 90% for ASD,
whereas the concordance rates in dizygotic twins
are 5% and 10%, respectively. Previous studies
suggest autism displays a high degree of genetic
heterogeneity. Efforts to map disease genes using
linkage analysis have found evidence for autism
loci on 20 different chromosomes. Regions
implicated by multiple studies include 1p, 5q,
7q, 15q, 16p, 17q, 19p, and Xq (2). Moreover,
microscopy studies have identified cytogenetic
abnormalities in >5% of affected children,
involving many different loci on all chromo-
somes (3). In some rare syndromic forms of
autism, such as Rett syndrome (4) and tuberous
sclerosis (5), mutations in a single gene have
been identified. Otherwise, neither linkage nor
cytogenetics has unambiguously identified spe-
cific genes involved.
Genetic heterogeneity poses a considerable
challenge to traditional approaches for gene
mapping (6). Some of these limitations are
overcome by methods that rely on the direct
detection of functional variants, which in most
cases are de novo events. New array-based
technologies can detect differences in DNA copy
number at much higher resolution than cyto-
genetic methods (7) and, hence, might reveal
spontaneous mutations that were previously
unidentified. These techniques have shown an
abundance of copy number variants (CNVs) in
humans (8, 9), and the same methods have been
used to find de novo chromosome aberrations
below the resolution of microscopy in children
with mental retardation and dysmorphic features
(10–14), including patients with syndromic
forms of autism (15). Yet, the association of
spontaneous CNVs in idiopathic autism has not
been systematically investigated. Thus, a large-
scale study of genome copy number variation in
ASD was needed. We have performed high-
resolution genomic microarray analysis on a
sample of 264 families to determine the rate of
de novo copy number mutation in unaffected and
affected children.
Our study focused on a sample of 264 fami-
lies, including 118 “simplex” families contain-
ing a single child with autism, 47 “multiplex”
families with multiple affected siblings, and 99
control families with no diagnoses of autism.
The majority of patients came from the Autism
Genetic Resource Exchange (AGRE) and from
the National Institute of Mental Health (NIMH)
Center for Collaborative Genetic Studies of
Mental Disorders. Additional families were ob-
tained through the authors (T.C.G., J.S.S., J.B.,
and D.S). Efforts were made at all of the col-
lecting sites to exclude cases of syndromic
autism (i.e., those with severe mental retarda-
tion or other congenital anomalies) and to
exclude known cytogenetic abnormalities.
Identities of all subjects and their parents were
coded so that analysis could be done blind to
affected status while maintaining knowledge of
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the parent-child relations.We performed whole-
genome scans on all parents, patients, and
unaffected children. Affected or unaffected sib-
lings of many patients were included in the
study as independent cases or controls, respec-
tively; thus, the entire sample yielded a com-
plete parent-child “trio” for each of 195 patients
and 196 healthy individuals. (See supplemen-
tary methods and table S1 for more extensive
details on the patient sample.)
We analyzed DNA samples, prepared from
either whole blood or Epstein-Barr virus (EBV)
immortalized B cells or both, collected from
subjects and their biological parents. Genome
scans were performed by ROMA, a form of
comparative genomic hybridization described
previously (8, 16). We performed two-color
assays by cohybridizing each sample to an
oligonucleotide array, and we used a standard
reference genome, SKN1, for comparison.
Assays were performed in duplicate with dye-
swap. The array consisted of 85,000 probes,
providing a mean resolution of one probe every
35 kb. Log intensity ratios from duplicate scans
were averaged, and normalized ratio data were
segmented by a Hidden Markov Model to define
CNVs relative to reference (8) (with minor
modifications).
Detecting copy number variation from array
data is an error-prone process, and so procedures
were followed to ensure that events we detected
in subjects were in fact de novo: not false-
positive in the subject, and not false-negative in
either biological parent. A flow chart of our
procedure for finding and testing de novo
mutations is depicted in Fig. 1. CNV regions
detected in subjects were considered only if they
involved at least three consecutive probes and
had an overall likelihood measure >0.9 (8).
Then, CNVs were disregarded if they were 60%
similar in probe content to a variant detected in
the set of all parents, where similarity between
two CNVs is defined as (the number of common
probes)/(the total number of probes in either
CNV). This step was done in order to simulta-
neously filter out any CNVs present in the
biological parents and to eliminate common
polymorphic loci that would incorrectly appear
to be de novo. The latter can occur, for example,
when the parents and the reference are all
heterozygous for a deletion and 0 or 2 copies
are transmitted to the child. These two proce-
dures greatly reduce the total number of can-
didates requiring validation.
We then further examined each candidate
variant by a more careful assessment of the
parents for the presence of the CNV, using a
relaxed set of criteria for its presence (see legend
to Fig. 2), to rule out false-negatives. If at that
point the variant in the subject still appeared to be
de novo, that is, present in the child but not in
either parent, we tested parentage using multiple
informative genetic markers. We then conducted
additional validation of the suspect de novo
lesion in parents and subjects, including Dpn
II–ROMA using 390K arrays, CGH using
Agilent 244K arrays, cytogenetics, and micro-
satellite genotyping. When de novo mutations
were detected in DNA derived from an EBV-
immortalized cell line, we sought to repeat
analysis on DNA derived from an independent
blood sample and found confirmation in 11 out of
12 available cases.
One example of the detection and confirmation
of a de novo CNV is illustrated in Fig. 2. We
detected a 1.1-Mb deletion of 20p13 in a childwith
the diagnosis of Asperger syndrome. This deletion
involves ~27 genes, including the oxytocin gene
OXT, a particularly noteworthy candidate in light
of studies in humans and rodents that find evidence
for the role of oxytocin in regulating social
cognition (17, 18). All validated de novo subject
variants are listed in Table 1 with a description of
each type of mutation, its methods of validation,
genomic location, gene content, and information
on the subject’s affected status and family type
(simplex, multiplex, or control). Additional details
regarding these and other variants detected in this
study are provided in table S2. Initially, we
detected 19 de novo CNVs in 17 individuals. In
one family, subsequent analysis of the parental
chromosomes by fluorescence in situ hybridization
(FISH) determined that the two de novo events
detected (a duplication and deletion) were the
result of an unbalanced translocation inherited
from an unaffected father who carries the balanced
reciprocal translocation. In conclusion, 17 CNVs
were confirmed to be de novo in 16 individuals
(Table 1), consisting of 14 patients and 2 controls.
The majority of these mutations are novel, and
only the largest of them (all CNVs >4 Mb in size)
have been reported previously in the literature
(19–21).
These data show that spontaneous copy
number changes are more frequent in patients
Fig. 1. Procedure for the
detection of de novo CNVs.
The flow diagram describes
the step-by-step procedure
for identifying regions of al-
tered copy number that are
present in a child and not in
the biological parents.
Obtain DNAs from patients, 
siblings, and biological parents
Coded
Status
85K Data
Subject
CNVs
Control
CNVs (from 
all parents)
CNV
database
ROMA
CNV discovery (HMM)
Rare CNVS Parental 85K 
data
Candidate 
de novo 
CNVs
Identify 
“common” CNVs
Type these markers 
in the parents of 
each subject (using 
relaxed algorithm)
Confirmed 
de novo 
CNVs
Validation by 390K ROMA
De novo 
CNVs in 
patients
De novo 
CNVs in 
controls
Decode 
status
Further validation and characterization by FISH, 
cytogenetics, and microsatellite genotyping
Validate
parentage
20 APRIL 2007 VOL 316 SCIENCE www.sciencemag.org446
REPORTS
 
o
n
 N
ov
em
be
r 3
, 2
01
1
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
with ASD (14 out of 195) than in unaffected
individuals (2 out of 196), with an association
that is statistically significant (P = 0.0005). The
frequency of spontaneous mutation was 10% (12
out of 118) in our sample of sporadic cases and
3% (2 out of 77) in our sample of cases from
multiplex families (Table 2). The frequency of
spontaneous mutation in unaffected individuals
was 1% (2 out of 196). Most mutations in
persons with autism were deletions (12 out of
15); however, the two mutations detected in
controls were both duplications.
The strong association of de novo CNVs with
ASD is consistent with such mutations being a
primary cause in most cases rather than merely
contributory. A further line of evidence to support
this claim is the higher proportion of females
among cases with de novo mutations, where the
genders of patients consisted of 9 males and 5
females (1.8:1) compared with 163 males and 32
females (5:1) in our overall sample. This reduced
gender ratio suggests that de novo CNVs that are
detectable by our method have increased pene-
trance and, thus, contribute to disease more
equally in females and males.
A lower rate of de novomutation in multiplex
families is also consistent with a causal role for
the mutations reported in this study. An
alternative hypothesis is that de novo CNVs are
associated with autism indirectly, the conse-
quence of a “fragile-genome disorder” in which
many lesions in addition to the ones we detected
occur due to an unknown environmental or
heritable factor. We regard this alternative as
unlikely; first, becausewewould expect evidence
for such a disorder to be present equally in
multiplex or simplex families. Another observa-
tion that is inconsistent with this alternative
hypothesis is that we do not see patients with
copy number mutations littered throughout the
genome. Instead, de novo CNVs typically
involve a single mutational event.
Two of the patients mentioned in Table 1 have
a formal diagnosis of Asperger syndrome, which
suggests that spontaneous chromosomal imbal-
ances are common across the whole spectrum of
the disorder. We examined whether there were
many cases of mental retardation [defined as
having a nonverbal intelligence quotient (IQ) less
than 70] among patients in whomwe detected de
novomutations. Clinical data on 60 patients were
obtained, and these data included five of the
patients in Table 1. The average nonverbal IQ of
five cases was 85 and the minimum was 70.
Fig. 2. Detection and validation of a spontaneous deletion in a patient with
Asperger syndrome. CNVs were detected in patient scans using the standard
HMM. Parents were ascertained and determined to have no change in copy
number using an algorithm with relaxed criteria. These second detection criteria
included (1) detection by an HMM with reduced stringency (false-positive
expectation set at 1%), and median probe ratio ≤0.91 or ≥1.1. Probe ratio data
are shown for the patient SK-135 (blue) and the mother (red) and father (green)
for 85K ROMA (A) and 244K Agilent CGH (B) platforms. The map of annotated
known genes was obtained from the UCSC Genome Browser, May 2004 assembly
(30). The genomic region estimated to be deleted is shown in (C) outlined in red.
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Although this average was lower than the
average for all patients (100), these data indicate
that the de novo mutations identified in our study
were not found generally in patients with mental
retardation.
Because the difference in rate between autism
and control is so marked, we can make a fair
presumption that many of the lesions we
observed contribute to the disorder. However,
the observation of a de novo mutation in a single
family is not sufficient evidence to prove that a
mutation is causal, nor does it provide un-
equivocal evidence for the involvement of a
specific gene in autism.When an individual gene
candidate can be identified, because the mutation
affects a single gene or a small number of
functional candidates, a straightforward path to
validation can be planned, involving sequencing
and higher-resolution CNVanalysis in additional
samples. The principle is illustrated in the recent
study by Durand et al. where an intensive survey
of variation in a candidate gene, SHANK3,
revealed multiple additional variants, including
de novo and inherited mutations (22). SHANK3
is one of the genes within the 4.3-MB deletion on
chromosome 22q13 that we reported in Table 1,
and this region is also a site of recurrent deletions
in autism (20). Thus, an aggregate of deletions
and coding variants that occurs in patients and
not in controls can provide further evidence of a
gene’s role in disease once that candidate gene is
identified by copy number mutation.
Some of the genes contained within the de
novo CNVs we identified are good candidates for
further study. A list of all RefSeq genes that
overlap with the de novo mutations identified in
this study is shown in table S3. Five of the de
novo events we detected involved only a single
gene and are worthy of mention. A spontaneous
deletion was identified involving exons 2–8 of the
putative sterol desaturase FLJ16237. Little is
known about the function of FLJ16237, but its
expression has been detected by in situ hybridiza-
tion in the superior temporal gyrus of fetal brain
(D.H.G.). In a pair of monozygotic twins
concordant for autism, we detected a spontaneous
deletion of exon 1 of the putative sodium
bicarbonate cotransporter SLC4A10. Mutations
of the related gene, SLC4A4, are associated with
renal tubular acidosis and mental retardation (23).
Other single-gene mutations were detected af-
fecting ataxin 2–binding protein 1 (A2BP1/FOX-1)
and the fragile histidine triad gene (FHIT) (Table 1).
A2BP1 is known to interact with the SCA2, the
gene for spinocerebellar ataxia type 2, and
A2BP1 mutations have been identified in mental
retardation and epilepsy (24). We observed two
independent spontaneous mutations of FHIT, a
locus that is one of the most fragile sites in the
human genome (25), but one of these was not
detected in an extract of the original blood from
which the cell line was derived.
All five single-gene mutations we detect
involve unusually large genes, the smallest of
which (SLC4A10) spans 359 kb of the genome.
All four target genes rank among the top 3% of
human genes by length. This is consistent with
previous observations that large genes are
frequently located within unstable regions of the
genome (26). Our simulations, made by randomly
permuting the location of our CNV regions,
indicate that this result may simply reflect that
large genes, by virtue of their size alone, are more
likely to be affected by random rearrangements.
Whatever the explanation, large genes do play
prominent roles in spontaneous genetic disorders
in humans, such asDuchennemuscular dystrophy
(27), retinoblastoma (28), and neurofibromatosis
(29); and the same could be true for autism.
These studies do not address the mechanisms
by which structural mutations of genes contribute
to autism. Changes in dosage or structure of
genes within a lesion could have quantitative
effects on gene function, including haploinsuffi-
ciency or altered transcription patterns. Alterna-
tively, hemizygous deletion could result in total
Table 2. Increased frequency of de novo CNVs in autism. The numbers of de novo events are listed for
our autism sample and for each category of family separately (simplex, multiplex, and nonautism
control). The difference between cases and controls was examined, and the statistical significance was
determined using Pearson’s chi-square test with simulated P value from 2000 replicates. The P value for
the difference in frequency between cases from simplex and multiplex families was also determined.
Sample group n CNVsde novo Ratio
P value
c2 Multiplex/simplex
Simplex autism 118 12 0.102 0.0005 0.043
Multiplex autism 77 2 0.026 0.59
Simplex + multiplex 195 14 0.072 0.0035
Controls 196 2 0.010
Table 1. Spontaneous CNVs detected by ROMA. A description of 17 de novo
CNVs in 16 subjects is provided, alongwith themethods used for its validation.
The number of unique RefSeq genes within each CNV region is indicated, and
when the locus apparently encompasses only a single gene, the gene symbol is
listed. Types of validation included (A) higher-resolution microarray scans by
390K ROMA or Agilent 244K CGH, (B) G-banded karyotype, (C) FISH, and (D)
microsatellite genotyping. References are listed for four cases where similar de
novo CNVs were previously reported in the literature.
Individual Locus Startposition Length
CN
change
Family
type Diagnosis Gender Validation # Genes
Single-gene
targets Ref.
63-144-2575 and
2667
2q24.2 162,212,720 99,252 Loss Simplex Autism Female A 1 SLC4A10
61-2710-3 2q37.2-q37.3 236,414,455 6,286,648 Loss Simplex Autism Male A, B, D 50 (19)
Van69-258900 2q37.3 238,217,066 4,484,037 Loss Simplex Autism Male A, D 43 (19)
89-3507-1 3p14.2 60,746,033 101,507 Loss Simplex Autism Male A 1 FHIT
63-562-6612 3p14.2 61,072,100 293,096 Gain Simplex Autism Male A 1 FHIT
AU010604 6p23 13,997,280 1,264,651 Loss Multiplex Autism Male A, D 2
13q14.12-q14.13 44,199,441 1,943,737 Loss A, D 13
AU072203 7p21.1 15,160,118 151,880 Loss Simplex Autism Male A 1 FLJ16237
AU032903 10q11.23-q21.2 50,562,149 10,916,362 Gain Multiplex Autism Male A, B 23
60-3061-4 15q11-q13.33 18,526,971 12,229,800 Gain Simplex Autism Male A, B 30 (21)
AU077504 16p13.3 5,992,836 207,980 Loss Simplex Autism Female A, B, C, D 1 A2BP1
CG2061 16p11.2 29,578,715 502,574 Loss Simplex Asperger’s Female A, C, D 27
71-259100 20p13 75,912 291,959 Loss Simplex Autism Female A, C, D 7
SK-135-C 20p13 2,785,194 1,169,205 Loss Simplex Asperger’s Male A, D 23
89-3524-100 22q13.31-q13.33 45,144,027 4,321,856 Loss Simplex Autism Female A, B, C, D 30 (20)
NA10857 2p16.1 58,394,177 2,786,284 Gain Control Unaffected Male A 7
AU070807 20p13-p12.3 111,824 5,316,286 Gain Simplex Unaffected Female A 69
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loss of function if it is compounded by recessive
mutation or monoallelic exclusion of the remain-
ing allele. A genomic rearrangement may also
disrupt regulatory elements that influence the
expression of neighboring genes; thus, in some
cases, a gene related to autismmay lie adjacent to
the deletion or duplication.
Our findings have implications for an under-
standing of the genetic basis for ASDs. An
important feature of the de novo CNVs we report
is that each is individually rare in the population
of patients. None of the genomic variants we
detected were observed more than twice in our
sample, and most were seen but once. Although
our sample size is small, these results suggest that
lesions at many different loci can contribute to
autism, a result consistent with the findings from
cytogenetics, as well as consistent with the failure
to find common heritable variants with a major
effect on disease risk. Lack of recurrence may in
fact reflect an underlying reality that autistic
behavior can result from many different genetic
defects. This would be consistent with the hy-
pothesis that the common features of autism such
as failure to develop social skills and repetitive
and obsessive behavior may in fact be the con-
sequence of a reaction to many different cogni-
tive impairments, drawing their “commonality”
from a normal but maladaptive programmed
response of humans early in development to
those diverse impairments.
We do not know the full contribution of
spontaneous mutation to autism. Population
studies divide autism into sporadic and familial
or “multiplex.”Ourwork provides clear evidence
that these two classes are indeed genetically
distinct. The rate of de novo mutation in mul-
tiplex families was significantly lower than for
sporadic cases (Table 2, P = 0.04), as would be
expected if there were two different genetic
mechanisms contributing to risk: spontaneous
mutation and inheritance, with the latter being
more frequent in families that have multiple
affected children.
The rate of spontaneous mutation that we
detect in autism is an underestimate. Adding the
known rate of cytogenetically visible abnormal-
ities, the total frequency of de novo variation
detectable in sporadic cases is ~15% at our
current resolution. Because of the limited resolu-
tion of genome microarray scans, we expect that
we fail to detect the vast majority of CNVs.
Much smaller deletions or even point mutations
can produce the same consequences as the larger,
more easily detectable events. As technology for
discovering spontaneous germline mutation in
children improves, the proportion of autism cases
with detectable events is bound to rise.
We can incorporate a high rate of spontaneous
mutation in a genetic model that accounts for both
sporadic and familial forms of the disease, based
on new mutations that cause autism by haploin-
sufficiency but have incomplete penetrance,
especially in females. Such individuals who
escape the phenotypic consequences can then pass
on the mutation in an apparently dominant fashion
to their children. This model makes very clear
predictions that can be tested in the short term.
Our findings highlight how methods for
directly detecting CNVs genomewide provide a
powerful alternative to traditional gene-mapping
approaches for discovering genetic risk factors in
autism and in other disorders of complex etiolo-
gy. Improved technologies for mutation detec-
tion, such as high-throughput DNA sequencing
and tiling-resolution oligonucleotide arrays,
promise to improve our power to identify new
mutations associated with disease.
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Raman-Assisted Crystallography
Reveals End-On Peroxide Intermediates
in a Nonheme Iron Enzyme
Gergely Katona,1 Philippe Carpentier,1 Vincent Nivière,2 Patricia Amara,1 Virgile Adam,3
Jérémy Ohana,1 Nikolay Tsanov,1 Dominique Bourgeois1,3*
Iron-peroxide intermediates are central in the reaction cycle of many iron-containing biomolecules.
We trapped iron(III)-(hydro)peroxo species in crystals of superoxide reductase (SOR), a nonheme
mononuclear iron enzyme that scavenges superoxide radicals. X-ray diffraction data at 1.95 angstrom
resolution and Raman spectra recorded in crystallo revealed iron-(hydro)peroxo intermediates with
the (hydro)peroxo group bound end-on. The dynamic SOR active site promotes the formation of
transient hydrogen bond networks, which presumably assist the cleavage of the iron-oxygen bond in
order to release the reaction product, hydrogen peroxide.
The interaction of dioxygen with iron-containing proteins is important in manybiological processes, including transport,
metabolism, respiration, and cell protection. The
reaction of oxygen or its reduced derivatives,
superoxide and hydrogen peroxide, with iron en-
zymes often involves short-lived iron-peroxide
intermediates along the reaction cycle (1, 2).
Heme-based peroxidases, catalases, and many
oxygenases promote heterolytic cleavage of the
peroxide oxygen-oxygen bond to form high-
valence reactive iron-oxo species. In contrast,
other iron enzymes, such as superoxide reductase
(SOR) (3, 4), are fine-tuned to cleave the iron-
oxygen bond and avoid the formation of po-
tentially harmful iron-oxo species. Although the
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